CYFIP1 Antibody (23GB1605)
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-51330
Key Product Details
Species Reactivity
Human, Mouse, Rat
Applications
Western Blot, Flow Cytometry, Immunocytochemistry/ Immunofluorescence, Knockdown Validated
Label
Unconjugated
Antibody Source
Monoclonal Rabbit IgG Clone # 23GB1605
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
A synthesized peptide derived from human CYFIP1 (Uniprot: Q7L576)
Clonality
Monoclonal
Host
Rabbit
Isotype
IgG
Applications for CYFIP1 Antibody (23GB1605)
Application
Recommended Usage
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Immunocytochemistry/ Immunofluorescence
Optimal dilutions of this antibody should be experimentally determined.
Knockdown Validated
Optimal dilutions of this antibody should be experimentally determined.
Western Blot
Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Affinity purified
Formulation
PBS (pH 7.4), 50% glycerol
Preservative
0.02% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at -20C. Avoid freeze-thaw cycles.
Background: CYFIP1
Alternate Names
cytoplasmic FMR1 interacting protein 1, cytoplasmic FMR1-interacting protein 1, FLJ45151, KIAA0068cytoplasmic FMRP interacting protein 1, P140SRA-1, selective hybridizing clone, SHYC, Specifically Rac1-associated protein 1, SRA1, Sra-1
Gene Symbol
CYFIP1
Additional CYFIP1 Products
Product Documents for CYFIP1 Antibody (23GB1605)
Product Specific Notices for CYFIP1 Antibody (23GB1605)
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...